Prognostic significance of WT1 gene expression in pediatric acute myeloid leukemia
- 5 June 2007
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 49 (2) , 133-138
Abstract
Background The Wilms Tumor gene (WT1) encodes a transcription factor involved in kidney development and malignancy. WT1 expression in a subpopulation of early CD34+ cells has suggested its involvement in hematopoiesis. WT1 is aberrantly expressed in leukemias. High expression of WT1 at diagnosis has been associated with unfavorable prognosis in adult acute myeloid leukemia (AML). The prognostic relevance of WT1 expression in pediatric AML was evaluated in only one study, including 47 patients, which showed that very low levels of WT1 at presentation were associated with an excellent outcome. To test the validity of these findings we measured levels of WT1 in 41 newly diagnosed pediatric AML of the non‐M3 FAB subtype. Procedure Patients were treated according to an AML‐BFM 83‐based protocol in a single institution. Mononucleated cells obtained from presentation BM aspirates were cryopreserved and later thawed and used for total RNA extraction and cDNA synthesis. The quantitative assessment of WT1 transcripts was made by real‐time PCR (RQ‐PCR). WT1 transcripts values were normalized with respect to the number of ABL transcripts. Results WT1 levels were significantly higher in patients bearing favorable chromosome abnormalities, t(8;21) and inv(16) (P = 0.002). Higher levels of WT1 expression were unexpectedly associated with a higher probability of overall survival by Cox regression analysis (P = 0.002). Multivariate regression analysis could not discriminate between the effects of WT1 and cytogenetics on survival. Conclusions Higher WT1 expression was associated with favorable cytogenetics subtypes and accordingly with better outcome in children with AML in this study. Pediatr Blood Cancer 2007;49:133–138.Keywords
This publication has 34 references indexed in Scilit:
- Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemiaLeukemia, 2005
- Multiplex Real-time RT–PCR for Prospective Evaluation ofWT1and Fusion Gene Transcripts in Newly DiagnosedDe NovoAcute Myeloid LeukemiaLeukemia & Lymphoma, 2004
- The relationship of patient age to the pathobiology of the clonal myeloid diseasesSeminars in Oncology, 2004
- Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer programLeukemia, 2003
- Significant Correlation Between the Degree of WT1 Expression and the International Prognostic Scoring System Score in Patients With Myelodysplastic SyndromesJournal of Clinical Oncology, 2003
- Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patientsLeukemia, 2002
- Utility of WT1 as a Reliable Tool for the Detection of Minimal Residual Disease in Children with LeukemiaPediatric and Developmental Pathology, 2002
- Wilms' Tumor Gene Expression by Normal and Malignant Human B LymphocytesLeukemia & Lymphoma, 2000
- Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locusCell, 1990
- Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative GroupBritish Journal of Haematology, 1976